Support is available for Ribasphere^® RibaPak^® treatment

Aspire^® is a program offering live support for patients, prescribers, and pharmacists. This program helps provide financial and educational assistance to ensure patients have access to their hepatitis C medicines and achieve treatment goals. For eligible patients, Aspire offers the following:

• Reimbursement Solutions – Reimbursement Specialists research your insurance benefits for Ribasphere RibaPak, assist with insurance prior authorization and appeals and help guide you to alternative forms of financial support.
  
  
• Nurse Hotline – Dedicated registered nurses are available by phone to help answer medical questions about your hepatitis C medications.
  
  
• Ribasphere RibaPak Dose Reduction Bridge Program – This program allows patients currently on Ribasphere RibaPak to be easily dose-reduced, as prescribed by their healthcare provider.
  
  
• Patient Assistance Program (PAP) – This program provides Ribasphere RibaPak for free to patients with limited or no health insurance, are not covered by other patient assistance programs and who meet the income eligibility requirements.

To enroll into the Aspire program or speak with a dedicated team of experts, call toll-free at:

The CoPay Savings Card can help reduce your medication costs

• To print an instant CoPay Savings Card, visit www.RibaPak.com/savings

Here's how it works:

• Majority of patients will only pay $10 toward insurance copay
  
  
• The CoPay Savings Card will pay up to a maximum benefit of $65 toward your monthly copayment
  
  
• The CoPay Savings Card is good for up to eighteen monthly fills of Ribasphere RibaPak
  
  
• You need only one Ribasphere RibaPak CoPay Savings Card to get these benefits

Eligibility Requirements:
CoPay Savings Card is available for self-pay patients and most commercially insured patients except those residing in Massachusetts. Patients covered by Medicare, Medicaid, TRICARE or other federal or state healthcare programs are not eligible. Patients must be 18 years of age or older to participate. CoPay Savings Card is valid for Ribasphere RibaPak product only.

INDICATION

Ribasphere (ribavirin, USP) in combination with peginterferon alfa-2a is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Ribasphere (ribavirin, USP) is contraindicated in:

• Patients with known hypersensitivity to Ribasphere (ribavirin, USP) or to any component of the tablet.
• Women who are pregnant.
• Men whose female partners are pregnant, plan to become pregnant, or are not using contraception.
• Patients with hemoglobinopathies (e.g., thalassemia major or sickle-cell anemia).
• In combination with didanosine. Reports of fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials.

Ribasphere (ribavirin, USP) and peginterferon alfa-2a combination therapy is contraindicated in patients with:

• Autoimmune hepatitis.
• Hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during treatment.
• Hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment.

WARNINGS AND PRECAUTIONS

Treatment with RIBASPHERE (ribavirin, USP) and peginterferon alfa-2a should be administered under the guidance of a qualified physician and may lead to moderate to severe adverse experiences requiring dose reduction, temporary dose cessation or discontinuation of therapy.

Ribasphere (ribavirin, USP) must not be used alone because ribavirin monotherapy is not effective for the treatment of chronic hepatitis C virus infection.

Ribasphere (ribavirin, USP) and peginterferon alfa-2a should be discontinued in patients who develop evidence of hepatic decompensation during treatment.

There are significant adverse events caused by ribavirin/peginterferon alfa-2a therapy, including severe depression and suicidal ideation, hemolytic anemia, suppression of bone marrow function, autoimmune and infectious disorders, ophthalmologic disorders, cerebrovascular disorders, pulmonary dysfunction, colitis, pancreatitis, and diabetes. The peginterferon alfa-2a package insert and medication guide should be reviewed in their entirety prior to initiation of combination treatment for additional safety information.

Pregnancy: Ribavirin may cause birth defects and/or death of the exposed fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients.

Anemia: The primary toxicity of ribavirin is hemolytic anemia (hemoglobin <10 g/dL), which was observed in approximately 13% of all ribavirin and peginterferon alfa-2a treated patients in clinical trials.

Hepatic Failure: Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including peginterferon alfa-2a. Cirrhotic CHC patients coinfected with HIV receiving highly active antiretroviral therapy (HAART) and interferon alfa-2a with or without ribavirin appear to be at increased risk for the development of hepatic decompensation compared to patients not receiving HAART.

Hypersensitivity: Severe acute hypersensitivity reactions (e.g., urticaria, angioedema, bronchoconstriction, and anaphylaxis) have been observed during alpha interferon and ribavirin therapy.

Renal Impairment: Ribasphere (ribavirin, USP) should not be used in patients with creatinine clearance <50 mL/min.

Pulmonary: Pulmonary symptoms, including dyspnea, pulmonary infiltrates, pneumonitis, pulmonary hypertension, pneumonia, and occasional cases of fatal pneumonia, have been reported during therapy with ribavirin and interferon. In addition, sarcoidosis or the exacerbation of sarcoidosis has been reported.

Bone Marrow Suppression: Pancytopenia (marked decreases in RBCs, neutrophils and platelets) and bone marrow suppression have been reported in the literature to occur within 3 to 7 weeks after the concomitant administration of pegylated interferon/ribavirin and azathioprine.

Pancreatitis: Ribasphere (ribavirin, USP) and peginterferon alfa-2a therapy should be suspended in patients with signs and symptoms of pancreatitis, and discontinued in patients with confirmed pancreatitis.

Laboratory Tests: Before beginning peginterferon alfa-2a/Ribasphere (ribavirin, USP) combination therapy, standard hematological and biochemical laboratory tests are recommended for all patients.

Drug Interactions: Nucleoside Analogues: NRTIs: In clinical trials, cases of hepatic decompensation (some fatal) were observed among the CHC/HIV coinfected cirrhotic patients receiving NRTIs. Patients receiving peginterferon alfa-2a/ribavirin and NRTIs should be closely monitored for treatment associated toxicities.

ADVERSE REACTIONS

Peginterferon alfa-2a in combination with ribavirin causes a broad variety of serious adverse reactions. The most common serious or life-threatening adverse reactions induced or aggravated by peginterferon alfa-2a and ribavirin include depression, suicide, relapse of drug abuse/overdose, and bacterial infections, each occurring at a frequency of <1%. Hepatic decompensation occurred in 2% of CHC/HIV patients. Nearly all patients in clinical trials experienced one or more adverse events.

For more information please see the Ribasphere RibaPak (ribavirin, USP) Tablets Full Prescribing Information. The peginterferon alfa-2a Package Insert should be reviewed in its entirety for additional safety information prior to initiation of combination treatment.

C001.00059